Apontis Pharma AG
Apontis Pharma AG markets and sells medical drugs for indication fields of internal medicine in Germany. It offers single pills and other pharmaceutical products with a focus on cardiovascular diseases, such as hypertension, dylipidemia, secondary prophylaxis, and asthma, as well as respiratory diseases and diabetes. The company was founded in 1946 and is based in Monheim am Rhein, Germany. Apont… Read more
Apontis Pharma AG (APPH) - Net Assets
Latest net assets as of June 2025: €31.62 Million EUR
Based on the latest financial reports, Apontis Pharma AG (APPH) has net assets worth €31.62 Million EUR as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€43.99 Million) and total liabilities (€12.37 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €31.62 Million |
| % of Total Assets | 71.89% |
| Annual Growth Rate | 28.05% |
| 5-Year Change | 796.89% |
| 10-Year Change | N/A |
| Growth Volatility | 407.84 |
Apontis Pharma AG - Net Assets Trend (2018–2024)
This chart illustrates how Apontis Pharma AG's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Apontis Pharma AG (2018–2024)
The table below shows the annual net assets of Apontis Pharma AG from 2018 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | €31.02 Million | +2.49% |
| 2023-12-31 | €30.26 Million | -27.19% |
| 2022-12-31 | €41.57 Million | +2.10% |
| 2021-12-31 | €40.71 Million | +1077.27% |
| 2020-12-31 | €3.46 Million | -25.49% |
| 2019-12-31 | €4.64 Million | -34.02% |
| 2018-12-31 | €7.03 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Apontis Pharma AG's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 4748.5% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | €8.50 Million | 27.40% |
| Other Components | €34.44 Million | 111.04% |
| Total Equity | €31.02 Million | 100.00% |
Apontis Pharma AG Competitors by Market Cap
The table below lists competitors of Apontis Pharma AG ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Linz Textil Holding AG
VI:LTH
|
$11.70 Million |
|
Forge Group Inc.
PINK:FIGP
|
$11.70 Million |
|
EE-HWA Construction Co. Ltd
KQ:001840
|
$11.71 Million |
|
Community Investors Bancorp Inc
PINK:CIBN
|
$11.71 Million |
|
Chuang's China Investments Limited
F:CUG
|
$11.70 Million |
|
Signal Advance Inc
PINK:SIGL
|
$11.70 Million |
|
Sun Peak Metals Corp
OTCQB:SUNPF
|
$11.69 Million |
|
SaintMed Public Company Limited
BK:SMD
|
$11.69 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Apontis Pharma AG's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 30,263,184 to 31,016,754, a change of 753,570 (2.5%).
- Net income of 753,569 contributed positively to equity growth.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €753.57K | +2.43% |
| Other Changes | €1.00 | +0.0% |
| Total Change | €- | 2.49% |
Book Value vs Market Value Analysis
This analysis compares Apontis Pharma AG's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.95x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 20.15x to 2.95x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2019-12-31 | €0.55 | €11.00 | x |
| 2020-12-31 | €0.41 | €11.00 | x |
| 2021-12-31 | €4.79 | €11.00 | x |
| 2022-12-31 | €4.89 | €11.00 | x |
| 2023-12-31 | €3.56 | €11.00 | x |
| 2024-12-31 | €3.72 | €11.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Apontis Pharma AG utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 2.43%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 1.55%
- • Asset Turnover: 1.09x
- • Equity Multiplier: 1.43x
- Recent ROE (2.43%) is above the historical average (-19.34%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2019 | -51.57% | -5.98% | 1.31x | 6.59x | €-2.86 Million |
| 2020 | -34.21% | -3.01% | 1.32x | 8.59x | €-1.53 Million |
| 2021 | -1.83% | -1.46% | 0.95x | 1.33x | €-4.82 Million |
| 2022 | 6.47% | 4.82% | 0.93x | 1.44x | €-1.47 Million |
| 2023 | -37.35% | -30.58% | 0.64x | 1.90x | €-14.33 Million |
| 2024 | 2.43% | 1.55% | 1.09x | 1.43x | €-2.35 Million |
Industry Comparison
This section compares Apontis Pharma AG's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $10,271,148,003
- Average return on equity (ROE) among peers: -99.00%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Apontis Pharma AG (APPH) | €31.62 Million | -51.57% | 0.39x | $11.70 Million |
| 26U (26U) | $6.75 Million | -514.32% | 1.08x | $248.33K |
| 27N0 (27N0) | $11.56 Million | -0.93% | 0.00x | $4.66K |
| China Resources Pharmaceutical Group Limited (640) | $90.18 Billion | 4.60% | 1.68x | $940.63 Million |
| CIG WIRELESS (6CW) | $27.09 Million | -110.19% | 3.19x | $56.65 Million |
| Solasia Pharma K.K (9SO) | $1.16 Billion | -167.91% | 0.18x | $34.42 Million |
| Akebia Therapeutics Inc (AX9) | $635.93 Million | -22.58% | 0.57x | $283.56 Million |
| Biofrontera AG (B8FK) | $-12.89 Million | 0.00% | 0.00x | $3.86 Million |
| AVALA RES (CVJ) | $91.87 Million | -27.32% | 0.11x | $113.22K |
| Deciphera Pharmaceuticals Inc (D05) | $341.69 Million | -52.37% | 0.33x | $2.11 Billion |